690999-15-6

Basic information

• Product Name: TD-6301
• Synonyms: TD-6301
• CAS NO: 690999-15-6
• Molecular Weight: 639.925
• Mol File: 690999-15-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: TD-6301(CAS DataBase Reference)
• NIST Chemistry Reference: TD-6301(690999-15-6)
• EPA Substance Registry System: TD-6301(690999-15-6)

Safety Data

• Hazardous Substances Data: 690999-15-6(Hazardous Substances Data)

Upstream product

• 134002-25-8 2,2-diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide 
• 690998-87-9 4-isopropylamino-1-(4-methoxypyrid-3-ylmethyl)piperidine 
• 690998-85-7 (S)-3-(1-carbamoyl-1,1-diphenylmethyl)-1-(7-oxohept-1-yl)pyrrolidine 
• 690999-16-7 4-{N-[7-((3-(S)-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-2-yn-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine 

Downstream Products

• 851645-51-7 4-{{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl]hept-1-yl}-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine naphthalene-1,5-disulfonic acid salt 
• 851645-45-9 4-{N-[7-((3-(S)-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine monosulfuric acid salt 
• 690999-23-6 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethylpyrrolidin-1-yl)hept-1-yl]-N-(ethyl)amino}-1-(2-methoxypyrid-3-ylmethyl)piperidine 
• 690999-21-4 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethylpyrrolidin-1-yl)-4-oxahept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine 

Relevant articles and documents

Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds

Processes and intermediates for preparing substituted 4-amino-1-(pyridylmethyl)-piperidine and related compounds in high yield and high purity are described. The substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds prepared by the describ

SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.